小剂量重组组织型纤维溶酶原激活剂治疗急性心肌梗死的疗效观察

Therapeutic Effect of Low-dose Recombinant Tissue-type Plasminogen Activator on Acute Myocardial Infarction

目的观察重组组织型纤维蛋白激活剂栓体舒(recombinant tissue plasminogen activator,rTPA)在急性心肌梗死治疗中的临床疗效和不良反应。方法小剂量重组组织型纤维蛋白溶酶激活剂(栓体舒)50mg于90min内静脉注入,治疗急性心肌梗死患者72例,观察血管再通的临床指标、不良反应及病死率。结果梗死相关血管再灌注率75%,6周病死率4.17%,出血发生率14.17%。结论小剂量栓舒静脉溶栓治疗急性心肌梗死较安全有效。

Objective To evaluate the therapeutic effect of recombinant tissue-type plasminogen activator(rTPA) on acute myocardial infarction.Methods 72 cases with acute myocardial infarction were treated by low-dose rTPA(50 mg) through 90 min vein injection,the clinic values of blood vessels recanalization,side effects and mortality were observed.Results Reperfusion rate of infarct related vessels was 75%,six-week mortality was 4.17%,bleeding rate was 14.17%.Conclusion It is safe and efficient of low-dose rTPA on acu...